Urokinase Market Report 2024

This Urokinase market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The urokinase market size has grown strongly in recent years. It will grow from $1.61 billion in 2023 to $1.7 billion in 2024 at a compound annual growth rate (CAGR) of 5.7%. The growth during the historic period can be attributed to the rising incidence of strokes and heart attacks, advances in clinical research, regulatory approvals for key indications, the development of initial formulations, and the expansion of healthcare infrastructure.

The urokinase market size is expected to see strong growth in the next few years. It will grow to $2.14 billion in 2028 at a compound annual growth rate (CAGR) of 5.8%. The anticipated growth during the forecast period can be attributed to a heightened focus on personalized medicine, the increasing prevalence of pulmonary embolism, rising investment in cardiovascular and stroke research, improvements in diagnostic and imaging techniques, a growing geriatric population, and a rise in obesity rates. Key trends expected during this period include advancements in personalized medicine, technological innovations in drug delivery systems, the integration of AI and digital health tools, progress in digital health platforms, and developments in clinical research.

The urokinase market is expected to grow due to the increasing prevalence of cardiovascular diseases. Cardiovascular diseases (CVDs) encompass a range of conditions affecting the heart and blood vessels, including heart attacks, strokes, and hypertension. The rise in CVD cases is attributed to factors such as higher obesity rates from sedentary lifestyles, poor dietary habits, and an aging population. Urokinase helps address the growing impact of cardiovascular diseases by dissolving blood clots that obstruct blood flow, thereby preventing heart attacks and strokes, restoring proper circulation, and reducing further cardiovascular damage. For instance, a report from the American College of Cardiology in August 2022 projected significant increases in major cardiovascular risk factors in the United States from 2025 to 2060. Diabetes is expected to rise by 39.3% to 55 million individuals, with substantial increases also anticipated for stroke (33.8% to 15 million), heart failure (33.4% to 13 million), ischemic heart disease (30.7% to 29 million), and heart attacks (16.9% to 16 million). This growing burden of cardiovascular diseases is driving the expansion of the urokinase market.

Key players in the urokinase market are focusing on reintroducing and commercializing pharmaceutical products for new indications to improve treatment effectiveness, market competitiveness, and patient access. This process involves bringing previously available or discontinued drugs back to the market for new uses and implementing strategies for successful marketing, distribution, and sales. For example, in May 2023, MBX Biosciences, a US-based biopharmaceutical company, collaborated with Sequel Pharma LLC, another US-based pharmaceutical firm, to reintroduce and commercialize kinlytic urokinase. The goal is to strengthen its presence in the catheter clearance market and enhance patient treatment outcomes. This partnership underscores the trend of leveraging strategic collaborations to revive and promote pharmaceutical products, ensuring they meet contemporary market demands and regulatory standards.

In August 2023, Eli Lilly and Company, a US-based pharmaceutical firm, acquired DICE Therapeutics Inc. for $48 billion. This acquisition is intended to enhance Eli Lilly's research and development capabilities in innovative therapies, potentially advancing their portfolio in thrombolytic treatments and related fields, including the development and optimization of therapies that could intersect with urokinase-based treatments. DICE Therapeutics Inc. is a US-based biotechnology company specializing in novel therapies for autoimmune and inflammatory diseases.

Major companies operating in the urokinase market are Thermo Fisher Scientific Inc., Mochida Pharmaceutical Co. Ltd., Bharat Serums and Vaccines Limited, Taj Pharmaceuticals Ltd., TTK Health Care Limited, Agrata Biotech Limited, Cerbios-Pharma SA, Microbix Biosystems Inc., Midas Pharma GmbH, ImaRx Therapeutics, Health Biotech Limited, Salvavidas Pharmaceutical Pvt. Ltd., BBT Biotech GmbH, Syner-Med (Pharmaceutical Products) Ltd., Echelon Biosciences Inc., Kraeber & Co GmbH, Samarth Life Science Pvt. Ltd., WUHAN HANWEISHI PHARMCHEM CO. LTD., Aetos Pharma, MITS CRITICAL CARE.

North America was the largest region in the urokinase market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the urokinase market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the urokinase market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Urokinase is a therapeutic enzyme used as a thrombolytic agent to dissolve blood clots. It functions by converting plasminogen into plasmin, which then breaks down fibrin, the main protein in blood clots. This treatment is employed in clinical settings to manage conditions like acute myocardial infarction and other blood clot-related disorders by restoring blood flow and minimizing the risk of severe complications from clot formation.

The primary forms of urokinase are urokinase powder and urokinase solution. Urokinase powder is the dry form of the enzyme, which is usually reconstituted with sterile water or saline before use. This powder form facilitates easier storage, transportation, and dosage preparation compared to liquid formulations. The production of urokinase involves both biotechnological methods and traditional extraction processes. It is used for various indications such as catheter clearance, coronary artery thrombosis, deep vein thrombosis, and pulmonary embolism. Urokinase is distributed through multiple channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and is used in different settings like hospitals, clinics, and other medical facilities.

The urokinase market research report is one of a series of new reports that provides urokinase market statistics, including urokinase industry global market size, regional shares, competitors with a urokinase market share, detailed urokinase market segments, market trends and opportunities, and any further data you may need to thrive in the urokinase industry. This urokinase market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The urokinase market consists of sales of urokinase thrombolytic agents, urokinase enzymes, and urokinase injections. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.